Anika Therapeutics, Inc. Net Fee Amt
Anika Therapeutics, Inc. (ANIK) had Net Fee Amt of $1.07 thousand as of 2026-07-28, per its S-8 filed 2026-07-29.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-07-29
- 2026-07-28: Net Fee Amt $1.07K.
| Period end | Net Fee Amt |
|---|---|
| 2026-07-28 | $1.07K S-8 · filed 2026-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |